EGFR and lung cancer: CNS metastases are a well-known adverse prognostic factor for overall survival (OS) in patients with lung cancer.5,6 Therefore, particularly for patients with EGFR-variant NSCLC, controlling CNS metastases is a crucial factor in determining their treatment approach.7 Thus, the properties of drugs that can effectively penetrate the BBB are highly important for the successful management of brain metastases.8